M. Bertelli, A. Castellani, G. La Malfa, S. Lassi, R. Salvini - Vol. 11, March 2005, Issue 1
Testo Immagini Bibliografia Indice
Uso di farmaci antidepressivi e antiansia nella persona
con disabilità intellettiva
Use of antidepressant and antianxiety agents in the person with intellectual
disability
1 Guaraldi GP, Ruggerini C, Russo A. I Disturbi Mentali associati al Ritardo Mentale. In: Pancheri P, Pfanner P, eds. Psicofarmacoterapia nei disturbi psichiatrici dell’infanzia e dell’adolescenza. Firenze: Scientific Press 1999.
2 Bertelli M, La Malfa GP, Castellani A, Anbertini G. (Adattamento italiano del volume di Deb S, Metthews T, Holt G, Bouras N. Practice guidelinee for the assessment and diagnosis of mental health problems in adults with intellectual disability). Pavilon Brington 2001, Ed. Erikson, Trento 2003.
3 Deb S, Weston SN. Psychiatric illness and mental retardation. Curr Opin Psychiatry 2000;13:497-505.
4 Matson JL, Bamburg JW, Mayotte FA, Pinkston J, Bielecki J, Kuhn D, et al. Psychopharmacology and mental retardation: a 10 year review (1990-1999). Res Develop Disabil 2000;21:263-96.
5 Bertelli M. Utilizzo dei farmaci antipsicotici e stabilizzatori dell’umore nel ritardo mentale – Consensus conference SIRM. Italian Journal of Psychopathology 2003;9(Suppl).
6 Moss S, Prosser H, Costello H, Simpson N, Patel P, Rowe S, et al. Reliability and validity of the PAS-ADD checklist for detecting disorders in adults with intellectual disability. J Intellect Disabil Res 1998;42:173-83.
7 Matson JL, Kazdin AE, Senatore R. Psychometric properties of the Psychopathology Instrument for Mentally Retarded Adults. Appl Res Ment Retard 1991;5:81-90.
8 Ryan RM, Rodden R, Sunada K. A model for interdisciplinary on site evaluation of people who have "Dual Diagnosis". NADD Newsletter 1991:8.
9 La Malfa GP, Notarelli A, Hardoy MC, Bertelli M, Cabras PL. Psychopathology and Mental Retardation: An Italian Epidemiological Study Using the PIMRA. Res Develop Disabil 1997;3:179-84 (tipo III).
10 Pancheri P. Errori terapeutici in psichiatria. Firenze: Scientific Press 2000.
11 Szymanski L. Integrative approach to diagnosis of mental disorders in retarded persons. In: Stark J, Melanoscino F, Alberelli N, eds. Mental Retardation and Mental Health. New York: Springer-Verlag 1988.
12 Dosen A, Day K. Treating Mental Illness and Behavior disorders in Children and Adults with Mental Retardation. Washington: American Psychiatric Press 2001.
13 Duggan L, Brylewsky J. Effecctiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. J Intellect Disabil Res 1999;43:94-104.
14 Cochrane Library. Issue 2. Update Software, Oxford, 2001.
15 Garber HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 1992;31:1157-60 (tipo II).
16 Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994;44:1309-12 (tipo V).
17 Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry 1997;36:1165-6 (tipo V).
18 Barak Y, Ring A, Levy D, Granek I, Szor H, Elizur A. Disabling compulsions in 11 mentally retarded adults: an open trial of clomipramine SR. J Clin Psychiatry 1995;56:459-61(tipo V).
19 Brasic JR, Barnett JY, Aisemberg P, Ahn SC, Nadrich RH, Kaplan D, et al. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. Psychol Rep 1997;81:755-67 (tipo V).
20 Wadlington WB, Rose M, Holcomb GW. Complications of trichobezoars: a 30-year experience. South Med J 1992;85:1020-2 (tipo V).
21 Lewis MH, Bodfish JW, Powell SB, Parker DE, Golden RN. Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. Am J Ment Retard 1996;100:654-65 (tipo II).
22 Sugama S, Kusano K, Okazaki M, Eto Y. The neuroendocrinological examinations in mentally retarded boy with self-injurious behavior (SIB) and the effect of naloxone, clomipramine and sulpiride on SIB. Rinsho Shinkeigaku 1992;32:890-2 (tipo V).
23 Holzer JC, Jacobson SA, Folstein MF. Treating compulsive self-mutilation in a mentally retarded patient. Am J Psychiatry 1996;153:133 (tipo V).
24 Luiselli JK, Blew P, Thibadeau S. Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury. Behav Modif 2001;25:62-78 (tipo II).
25 Langee HR, Conlon M. Predictors of response to antidepressant medications. Am J Ment Retard 1992;97:65-70 (tipo II).
26 Bachrach SJ, Walter RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr 1998;37:485-90.
27 Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-45 (tipo V).
28 Howland RH. Fluoxetine treatment of depression in mentally retarded adults. J Nerv Ment Dis 1992;180:202-5 (tipo V).
29 Linden MG, Tassone F, Gane LW, Hagerman RJ, Taylor AK, Hills JL. Compound heterozygous female with fragile X syndrome. Am J Med Genet 1999;83:318-21 (tipo V).
30 Friedman EH. Fluoxetine and aggressive behaviour. Pharmacopsychiatry 1996;29:121 (tipo V).
31 Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998;42:301-6 (tipo V).
32 Troisi A. Fluoxetine and aggression. Neuropsychopharmacology 1997;16:373-4 (tipo V).
33 Troisi A, Vicario E, Nuccetelli F, Ciani N, Pasini A. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry 1995;28:73-61 (tipo V).
34 Bodfish JW, Madison JT. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. Am J Ment Retard 1993;98:360-7 (tipo V).
35 Russell PS, Raj SE, John JK. Multimodal intervention for selective mutism in mentally retarded children. J Am Acad Child Adolesc Psychiatry 1998;37:903-4 (tipo V).
36 Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:870-3 (tipo V).
37 Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 2001;30:113-7 (tipo V).
38 Ricketts RW, Goza AB, Ellis CR, Singh YN, Singh NN, Cooke JC. Fluoxetine treatment of severe self-injury in young adults with mental retardation. J Am Acad Child Adolesc Psychiatry 1993;32:865-9 (tipo V).
39 Sovner R, Fox CJ, Lowry MJ, Lowry MA. Fluoxetine treatment of depression and associated self-injury in two adults with mental retardation. J Intellect Disabil Res 1993;37:301-11 (tipo V).
40 Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 1992;12:27-31 (tipo V).
41 La Malfa GP, Bertelli M, Conte M. Fluvoxamine and aggression in mental retardation. Psychiatr Serv 2001;52:1105 (tipo III).
42 Verhoeven WM, Veendrik-Meekes MJ, Jacobs GA, van den Berg YW, Tuinier S. Citalopram in mentally retarded patients with depression: a long-term clinical investigation. Eur Psychiatry 2001;16:104-8 (tipo V).
43 Verhoeven WM, Moog U, Wagemans AM, Tuinier S. Wolf-Hirschhorn (4p-) syndrome in a near adult with major depression; successful treatment with citalopram. Genet Couns 2002;13:297-301 (tipo V).
44 Raitasuo S, Virtanen H, Raitasuo J. Anorexia nervosa, major depression, and obsessive-compulsive disorder in a Down’s syndrome patient. Int J Eat Disord 1998;23:107-9 (tipo V).
46 Masi G, Marcheschi M, Pfanner P. Paroxetine in depressed adolescents with intellectual disability: an open label study. J Intellect Disabil Res 1997;41:268-72 (tipo V).
47 Prater JF, D’Addio K. Johanson-Blizzard syndrome – a case study, behavioral manifestations, and successful treatment strategies. Biol Psychiatry 2002;51:515-7 (tipo V).
48 Ramstad K, Loge JH, Sponheim E. Depression and Down syndrome. Tidsskr Nor Laegeforen 1998;118:2153-4 (tipo V).
49 Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7 (tipo II).
50 Wiener K, Lamberti JS. Sertraline and mental retardation with obsessive-compulsive disorder. Am J Psychiatry 1993;150:1270 (tipo V).
51 Campbell JJ, Duffy JD. Sertraline treatment of aggression in a developmentally disabled patient. J Clin Psychiatry 1995;56:123-4 (tipo V).
52 Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-6 (tipo V).
53 Patel NC, Crismon ML, Rush AJ, Frances A. Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders. Am J Health Syst Pharm 2001;58:1824-9 (tipo V).
54 Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001;11:267-77 (tipo V).
55 Bernstein L. Trazodone treatment of targeted aggression in a mentally retarded man. J Neuropsychiatry Clin Neurosci 1992;4:348 (tipo V).
56 Pasion RC, Kirby SG. Trazodone for screaming. Lancet 1993;341:970 (tipo V).
57 Ruedrich SL, Wilkinson L. A typical unipolar depression in mentally retarded patients: amoxapine treatment. Nerv Ment Dis 1992;180:206-7 (tipo V).
58 Clarke M, Oxman AD, eds. Cochrane Reviewers’ Handbook 4,1,4 [updated October 2001]. In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
59 Glanville J. Carrying out the literature search. In: Curran S, Williams CJ, eds. Clinical research in psychiatry: a practical guide. Oxford: Butterworth-Heinemann 1999, pp. 57-58.
60 NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. (CRD Report 4 2nd Edition). NHS Centre for Reviews and Dissemination, York 2001.
61 The Swedish Council on Technology Assessment in Health Care. Literature searching and evidence interpretation for assessing health care practices. (SBU Report No 119E). Stockholm: SBU 1996.
62 Tyrer SP. The assessment and physical treatment of affective disorders. Br J Hospital Medicine 1989;42:184-94.
63 Deb S. Epidemiology of psychiatric illness in adults with intellectual disability. In: Hamilton-Kirkwood L, Ahmed Z, Deb S, eds. Health Evidence Bulletins – Learning Disabilities (Intellectual Disability). Cardiff: NHS 2001.
64 Hurley AD, Folstein M, Lam N. Patients with and without intellectual disability seeking outpatient psychiatric services: diagnoses and prescribing pattern. J Intellect Disabil Res 2003;47:39-50.
65 Geller B, Reising D, Leonard HL. Critical Review of tricyclic antidepressant use in children and adolescent. J Am Acad Child Adolescent Psichiatry 1999;38:513-6.
66 Linnoila M, Higley D, Nielsen D. Serotonin and impulse control: from clinic to clone Eur. Neuropsychophopharmacol 1993;3:61.
67 Day K. Depression in moderately and myldly hanidicapped people. In: Dosen A, Engelen P, eds. Depression in the Mentally Retarded: Pratical Issues for Diagnosis and Treatment, Proceedings of the International Symposium. Netherlands: Leiden, PAO 1988, pp. 23-36.
68 Tsiouris JA, Adelman SA. Guideline/Information on Psychotropic and Antiepileptic drugs for Individuals with Developmental Disabilities. New York State Institute for Basic Research in Developmental Disabilities, Staten Island 1997.
69 Expert Consensus Guideline Series. Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 2000;105:159-226.
70 Sovner R, Pary RJ, Dosen A. Antidepressant drugs in Psychotropic Medication and Developmental Disabilities: The International Consensus Handbook. In: Reiss A, Aman MG, eds. Columbus, OH: Ohio State University Nisonger Center 1998, pp. 179-200.
71 Baghdadli A, Gonnier V, Aussilloux C. Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encephale 2002;28:248-54 (tipo V).
72 Drake ME, Pakalnis A, Phillips BB. Neuropsychological and psychiatric correlates of intractable pseudoseizures. Seizure 1992;1:11-3 (tipo II).
73 Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN, et al. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry 1994;33:270-6.
74 Verhoeven WM, Tuinier S. The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study. J Intellect Disabil Res 1996;40:502-8 (tipo V).
75 Colella RF, Ratey JJ, Glaser AI. Paramenstrual aggression in mentally retarded adult ameliorated by buspirone. Int J Psychiatry Med 1992;22:351-6 (tipo V).
75 Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998;102:427-37 (tipo II).
76 Holden B. Clonazepam therapy of aberrant behavior in a mentally retarded man. Tidsskr Nor Laegeforen 1997;117:3500-1 (tipo V).
77 Dent J. Catatonic syndrome following recovery from neuroleptic malignant syndrome. J Intellect Disabil Res 1995;39:457-9 (tipo V).
78 Gaind GS, Rosebush PI, Kalachnik JE, Hanzel TE, Sevenich R, Harder SR, 2002 (tipo V).
79 Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard, 2002;107:376-410 (tipo V).
80 Werry JS. Anxiolytics in MRDD. Mental Retardation and Developmental Disabilities. Res Rev 1999;5:299-304.
81 Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Brief report: clonazepam behavioral side effects with an individual with mental retardation. J Autism Dev Disord 2003;33:349-54 (tipo V).